"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

Continue reading Teva (TEVA): Baby-boomers give boost to generics

Teva (TEVA): Baby-boomers give boost to generics originally appeared on BloggingStocks on Wed, 14 Oct 2009 11:00:00 EST. Please see our terms for use of feeds.

"Few industries seem as well positioned for future growth as the generic drug industry," says small-cap growth stock specialist Tom Bishop.

In his BI Research newsletter, he explains, "With demographic pointing to an increasingly aging population, and healthcare costs spiraling out of control, low cost generic drugs are clearly part of the solution." Here's a look at generic drug maker Mylan (NYSE: MYL).

"High on the agenda of the Obama administration is to bring health care coverage to some 40 million Americans who are currently not covered.

Continue reading Generic gains from Mylan (MYL)

Generic gains from Mylan (MYL) originally appeared on BloggingStocks on Mon, 18 May 2009 12:30:00 EST. Please see our terms for use of feeds.